TITLE

BREAKING NEWS

PUB. DATE
February 2007
SOURCE
Pharmaceutical Technology;Feb2007, Vol. 31 Issue 2, p20
SOURCE TYPE
Trade Publication
DOC. TYPE
Article
ABSTRACT
The article presents a summary of news events from December 2006 to January 2007 in the pharmaceutical industry, which were published in the "Weekly Electronic Newsletter of Pharmaceutical Technology." In Berlin and Leverkusen, Germany, Bayer Schering Pharma was launched as a start up company after the acquisition of Schering AG by Bayer Group. On December 18, CEO G. Steven Burrill revealed that biotechnology stocks decreased by 14 percent in 2006.
ACCESSION #
23988669

 

Related Articles

  • Schering renamed.  // European Pharmaceutical Executive;Feb/Mar2007, p10 

    The article reports on Germany-based Schering AG's decision to change its name to Bayer Schering Pharma AG. The necessary entry in the commercial register took effect on December 29, 2006. The article also reports that the new logo has been mounted on Bayer Schering Pharma's headquarters in...

  • TOP 20 PHARMA: #15 BAYER SCHERING.  // Contract Pharma;2009, Vol. 11 Issue 6, p84 

    The article profiles Bayer Schering Pharma AG, the rank 15 among the top 20 pharmaceutical companies based in Leverkusen, Germany. It notes that it was founded in 1971 and handles 108,600 employees. It mentions its plan to strengthen its research and development initiative in 2009 through its 4...

  • Schering and Bayer seal drug ownership agreement. Chynoweth, Emma // ICIS Chemical Business;4/2/2007, Vol. 2 Issue 60, p33 

    This article reports that Bayer Schering Pharma and Novartis have settled a dispute over U.S. production of the interferon-based multiple sclerosis treatment Betaseron, sold in the U.S. as Betaferon. The deal sees Bayer Schering Pharma acquiring most of Novartis' Emeryville, California, site,...

  • Expert: 'Sea change coming' for health care, biotech. Smith, Nicholas // Inside Tucson Business;11/17/2008, Vol. 18 Issue 24, p3 

    The article focuses on a business forecast of G. Steven Burrill, chief executive officer (CEO) of Burrill and Co., for biotechnology and health care industries in Tucson, Arizona. Burril noted that the industries will have a shortage of capital, more money needed for less output and a switch to...

  • Collaborations Between Biotech And Pharmaceutical Companies: Oct. 1 - Nov. 24, 2009.  // BioWorld Insight;11/30/2009, Vol. 17 Issue 48, p6 

    The article presents the biotechnology and pharmaceutical companies collaborations between October 1, 2009 to November 24, 2009. AC Immune SA collaborated with Bayer Schering Pharma AG for diagnostic imaging of Alzheimer's disease. PepTcell Ltd. subsidiary Biocopea Ltd. partners with Sosei Group...

  • WHAT LIES AHEAD FOR BIOTECH IN 2011.  // Biotech Financial Reports;Feb2011, Vol. 18 Issue 2, p1 

    The article offers predictions for the biotechnology industry by biotech specialist and Burrill & Co. chief executive officer (CEO) G. Steven Burrill in the U.S. Burrill is seeing a dynamic industry in response to an environment that favors risk mitigated companies, emerging biotech markets...

  • European pharma consolidation generates quality spinoffs. Sheridan, Cormac // Nature Biotechnology;Dec2006, Vol. 24 Issue 12, p1458 

    The article focuses on the consolidation and acquisition of European pharmaceutical companies. The article discuses that Berlin based Schering company and two German companies are acquired by Bayer Healthcare, Germany, to establish Bayer-Schering Pharma. And the establishment will concentrate on...

  • COMPANY SPOTLIGHT -- Bayer Schering.  // PharmaWatch: CNS;Nov2010, Vol. 9 Issue 11, p19 

    The article features Bayer Schering Pharma AG. It relates that the pharmaceutical company is a research-based company which engaged in the manufacturing, developing, and marketing of pharmaceutical products. It says that the company focuses in four businesses including diagnostic imaging,...

  • EPIX Regains Vasovist Rights.  // BioWorld Today;9/5/2008, Vol. 19 Issue 173, p3 

    The article reports on the plan of EPIX Pharmaceuticals Inc. to regain full worldwide commercial rights for the imaging product Vasovist from Bayer Schering Pharma in 2008. EPIX hopes to have U.S. approval of the product by the end of the year. The firm had been awaiting word from Bayer on...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics